ABSTRACT In the present investigation a gas powered tablets  ( floating tablets)  of Captopril were prepared to increase the gastric retention time in order to improve the therapeutic effect of the drug by increasing its bioavailability. Captopril is antihypertensive drug, it is soluble in water; its maximum absorption is from the stomach and upper part of the intestine. The Gas powered tablets were prepared by direct compression method.   A present investigation  comprises a drug Captopril, a gas generating agent 6 to 18% sodium bicarbonate , water soluble polymers 40 to 60% HPMC 50 cps to get the desired controlled release over a period of 10 hrs. The prepare d tablets were subjected to post-compressional parameters such as hardness, friability, weight variation, thickness, drug content, lag time subsequently buoyancy time, and in-vitro  dissolution studies. Drug compatibility with excipients was checked by FTIR and DSC studies. The formulations C3 was found to be promising, which shows an in vitro  drug release of 91.32% in 10 hrs along with satisfactory floating lag time (2 min.27 sec.). All the formulations exhibited diffusion dominated drug release. KEYWORDS : Captopril, HPMC 50 cps, gastro-retentive floating drug delivery systems, hydro dynamically balanced systems.

ABSTRACT In the present research investigation, the effect of a novel- drug-drug solid dispersion approach on the dissolution of insoluble Lornoxicam (LOR) with soluble Ranitidine (RAN) was studied. Solid dispersion of LOR with RAN (8:150) was prepared by solvent evaporation technique. Solid dispersions were characterized by FTIR study. Solid dispersions were then compressed into fast dissolving tablets (FDTs) and evaluated for quality control tests. Long- tern treatment with NSAIDs may produce gastrointestinal symptoms for which histamine H ₂ -receptor antagonists may be prescribed. Thus, there is a need for a formulation that is not only providing improvement in solubility but at the same time reduces GI adverse effects of Lor. The solubility of Lor was increased in solid dispersion as observed from phase solubility study. Pharmacological studies on LOR FDTs were carried out in rats for establishing its gastric tolerance relative to marketed tablet (MT) containing 8 mg lornoxicam. MT caused significant gastric damage, our novel Lor FDTs at equimolar dose did not cause any GI damage. This gastric-sparing effect could be attributed to the beneficial action of RAN present in the formulation. KEYWORDS : Lornoxicam, Ranitidine, drug-drug solid dispersion.

ABSTRACT The present study was aimed towards the formulation and eveluation of fast disintegrating tablets by direct compression technology using Cimetidine as a model drug. Fast disintegrating tablet of Cimetidine was formulated using three Superdisintegrates in different concentrations i.e. 4%w/w, 6%w/w and 8%w/w and one disintegrates having concentration i.e. 4%w/w, 6%w/w and 8%w/w like Cross carmellose sodium, Crospovidone, Sodium Starch Glycolate. All the batches were prepared by direct compression method using the Cadmach Single punch tablet compression machine using 14X32 mm flat punch. Disintegration time and drug release were taken as the basis to optimize the immediate release tablet. Prepared tablets were evaluated for thickness, hardness, friability, uniformity of weight, disintegration time, wetting time and dissolution study Selected formulation was subjected to stability studies for thirty days which showed stability with regards to release pattern. KEYWORDS: Fast Disintegrating Tablet, Cimetidine, Superdisintegrants, Direct Compression Technology

ABSTRACT A Simple, precise, accurate and rapid RP-HPLC method developed and validated  for the simultaneous estimation of Artesunate  and Amodiaquine HCl in pure and pharmaceutical dosage form. The quantification was carried out using symmetry C ₁₈ column, 250 x 4.6 mm, i.d, 5μm particle size in isocratic mode, with mobile phase compressing of buffer and methanol in the ratio of 30:70 (v/v), pH 3 ± 0.5. The flow rate was 1 ml/min and the detection was carried out by UV detector dual i.e, 225 and 339 nm. The retention times were 2.39 and 3.99 mins for Amodiaquine HCl and Artesunate, respectively. The percentage recovery was found to be 99.40 and 99.83 % for Amodiaquine HCl and Artesunate, respectively. The method was validated as per ICH guideline. KEYWORDS: HPLC system, Amodiaquine HCl and Artesunate , UV detector.

ABSTRACT The present manuscript describes simple, sensitive, rapid, accurate, precise and economical Q- absorbance ratio method for the simultaneous determination of Ciprofloxacin and Metronidazole in combined dosage form. Absorbance ratio method uses the ratio of absorbances at two selected wavelengths, one which is an isoabsorptive point and other being the λ-max of one of the two components. Ciprofloxacin and Metronidazole show an isoabsorptive point at 295 nm in methanol. The second wavelength used is 279 nm, which is the λ-max of Ciprofloxacin in methanol. The linearity was obtained in the concentration range of 2-10 μg/ml for Ciprofloxacin and Metronidazole. The concentrations of the drugs were determined by using ratio of absorbances at isoabsorptive point and at the λ-max of Ciprofloxacin. The method was successfully applied to pharmaceutical dosage form because no interference. The results of analysis have been validated statistically and by recovery studies. KEY WORDS: Ciprofloxacin, Metronidazole, absorbance ratio method, isoabsorptive point, validation, simultaneous.

ABSTRACT Gastroretentive   drug   delivery   system   comprised   mainly   of   floating,   bioadhesive,   swelling,   high   density   and magnetic   systems   have   emerged   as   a   current   approaches   of   enhancing   the   bioavailability   and   controlled delivery   of   drugs   that   exhibit   an   absorption   window.   By   prolonging   the   gastric   emptying   time   of   the   dosage form,   these   systems   not   only   provide   controlled   release   of   the   drug   for   a   prolonged   period   but   also   present the   drug   in   an   absorbable   form   at   regions   of   optimal   absorption.   CR-GRDF   provides   a   means   to   utilize   all the   pharmacokinetic   (PK)   and   pharmacodynamic   (PD)   advantages   of   controlled   release   dosage   forms   for such   drugs.   Due   to   the   complexity   of   pharmacokinetic   and   pharmacodynamic   parameters,   in   vivo       studies are   required   to   establish   the   optimal   dosage   form   for   a   specific   drug.   For   a   certain   drug,   interplay   of   its pharmacokinetic   and   pharmacodynamic   parameters   will   determine   the   effectiveness   and   benefits   of   the CRGRDF compared to the other dosage forms. KEYWORDS:  floating, bioadhesive, swelling, high density and magnetic systems

ABSTRACT A Simple, precise, accurate and rapid RP-HPLC method developed and validated  for the simultaneous estimation of Simvastatin  and Coenzyme Q10 in pure and formulated dosage form. The quantification was carried out using symmetry C ₁₈ column, 250 x 4 mm, i.d, 5μm particle size in isocratic mode, with mobile phase compressing of Acetonitrile and Tetrahydrofuran (80:20). The flow rate was 1 ml/min and the detection was carried out by UV detector 254nm. The retention times were 6.47 and 3.64 min for Coenzyme Q10 and Simvastatin, respectively. Percentage recovery for SIM was 98.72-101.45% ,  while for COQ10, it was found to be in range of 98.00-101.27%. The method was validated as per ICH guideline. KEYWORDS: HPLC system, Coenzyme Q10 and Simvastatin , UV detector.

ABSTRACT: Two simple spectrophotometric methods have been developed for simultaneous determination of Amlodipine besylate and Telmisartan in tablet formulation. Method 1 is Absorbance correction method, which is  based on determination of Amlodipine besylate at 362 nm using its absorptivity value and Telmisartan at 292 nm. Method 2 is based on Absorbance ratio in which wavelengths selected were 326 nm, an isoabsorptive point and 292 nm as λmax of Telmisartan. Linearity was observed in the concentration range of 0.5-20, 0.5-15.5 µg/ml for AMLB and 3- 24, 3-24 µg/ml for TELM by method A and B respectively. The methods can be routinely adopted for quality control of these drugs in tablet. Recovery study was performed to confirm the accuracy of the methods. The methods were validated as per ICH guidelines. KEY WORDS: Amlodipine Besylate, Telmisartan, UV-Spectrophotometric determination, validation

ABSTRACT: A reverse phase high performance liquid chromatographic method was developed for the simultaneous estimation of Cefepime and Amikacin in injection formulation. The separation was achieved by   C18 (250 x 25mm) 25μm column  and Acetonitrile: water (10:90 v/v) as mobile phase, at a flow rate of 1 ml/min. Detection was carried out at 212 nm. Retention time of Amikacin and Cefepime was found to be 2.51 min and 6.23 min, respectively. The method has been validated for linearity, accuracy and precision. Linearity for Cefepime and Amikacin were in the range of 20-100 μg/ml. The percentage recoveries obtained for Cefepime and Amikacin were found to be in range of 98.22±0.56  and 99.63±0.57 respectively. Developed method was found to be accurate, precise, selective and rapid for simultaneous estimation of Cefepime and Amikacin in injection. The proposed method was successfully applied for the simultaneous estimation of both drugs in commercial injection preparation. KEYWORDS: Cefepime Hydrochloride, Amikacin Sulphate, RP-HPLC, Injection, Validation.

The simple, sensitive, accurate, precise, rapid and economical reverse phase high pressure liquid chromatographic method was developed for the simultaneous estimation of Furosemide and Spironolactone in combined tablet dosage form. The method was developed using an Inertsil C ₁₈  (250 x 4.6mm), 5μ column with a mobile phase consisting of Methanol:Water (70:30 v/v),pH 3.20 ±0.05, which was adjusted by o-phosphoric acid at a flow rate of 1.0 ml/min and detection was carried out at 236 nm. Retention times were found to be 3.64 min and 6.69 min for Furosemide and Spironolactone respectively. The linearity were found to be in the concentration ranges of 10-60 µg/ml & 25-150 µg/ml for Furosemide and Spironolactone respectively. The proposed method can be used for the estimation of these drugs in combined tablet dosage form. The result of analysis have been validated statistically and by recovery studies. KEYWORDS: Spironolactone, Furosemide, RP-HPLC, Tablet, Validation

The study was attempted to develop an alternative oral mucosal delivery of nanoparticles based system for antidepressant drug. The aim was to formulate a novel, transmucosal (buccal), polymeric nanoparticles based mucoadhesive system (diskettes) that could deliver fluoxetine hydrochloride with bypass first pass effect, with relative rapid onset, higher absorption and sustain release effect to increase bioavailability compared to oral absorption. In this study, the drug was encapsulated into poly (methyl vinyl ether / maleic anhydride) (Gantrez MS-955) mucoadhesive polymer nanoparticles. The drug bearing nanoparticles were prepared by emulsion solvent evaporation method. The effect of critical formulation variables like, polymer concentration, emulsifier concentration and process variable like rate of homogenization were studied for the particle size distribution; drug entrapment efficiency and mucoadhesion. The dependent variables of the formulations were optimized using 3 ²  full factorial designs and defined in mathematical equations. The desired values of response variables were found by contour plots generated using the design-expert ^®  8 version 8.0.6.1 software. The drug encapsulated polymeric nanoparticles were gently compacted along ethyl cellulose layer into small round shaped diskettes for facilitating buccal application in such a way that polymer layer adhere with buccal mucosa. The gently compacted diskettes gave dose precision through uniform drug distribution, high surface areas for better drug releases with sustain effect and without disrupter of nanoparticles. The in vitro studies of the diskettes included mucoadhesion and drug release profile were characterized. The in vivo studies were performed on rats. A significant improvement in the pharmacokinetic parameters of bioavailability like C _max , T _max and AUC was observed when compared with oral solution. The stability study was conducted on the optimized f ormulation at accelerated conditions. Key words:  nanoparticles, mucoadhesive diskettes, fluoxetine hydrochloride, factorial designs and Gantrez MS-955.